The Value of Nutritional Status in the Prognostic Analysis of Patients with AIDS-Related Lymphoma

Figures & data

Table 1 Nutritional and Immune Functional Indexes of 69 Patients with ARL with Different Clinical Outcomes (x̄±s)

	Total Median (Inter-Quartile Range)	Death Median (Inter-Quartile Range)	Survival Median (Inter-Quartile Range)	Death	Survival	P
BMI(Kg/m^2)	19.81 (18.27–23.38)	18.76 (17.12–19.82)	21.00 (18.62–23.53)	19.12±3.20	21.73±3.89	0.010
ALB(g/L)	37.60 (30.95–41.25)	30.65 (27.48–37.58)	39.20 (35.40–42.85)	31.68±7.76	38.86±6.07	0.000
PA(mg/L)	179.00 (118.00–246.00)	109.00 (73.25–171.75)	205.00 (144.50–260.00)	126.45±63.80	204.90±74.43	0.000
Hb(g/L)	115.00 (95.50–132.00)	98.50 (90.50–127.00)	118.00 (104.00–133.00)	104.95±23.75	118.45±22.95	0.032
ALC(×10^9/L)	0.94 (0.57–1.50)	0.67 (0.40–1.11)	0.97 (0.68–1.62)	0.75±0.48	1.20±0.74	0.014
CD4(Cells/μL)	162.00 (96.50–240.00)	101.00 (53.25–163.50)	193.00 (123.50–267.00)	121.20±106.56	203.49±109.62	0.006

Abbreviations: BMI, body mass index; ALB, albumin; PA, prealbumin; Hb, hemoglobin; ALC, absolute lymphocyte count.

Table 2 Univariate Analysis of the Clinical Characteristics and Prognosis of 69 Patients with ARL

Factors	Cases 69(%)	Survival/Death 49/20(Case)	χ^2	P
Gender			0.119	0.730
Male	57(82.61%)	41/16
Age(year)			0.050	0.824
≥60	9(13.04%)	6/3
BMI(Kg/m^2)			33.398	0.000
Normal(≥18.5)	49(71.01%)	38/11
Light(17–18.4)	16(23.19%)	11/5
Medium(16–16.9)	2(2.90%)	0/2
Heavy(<16)	2(2.90%)	0/2
ALB(g/L)			14.219	0.000
<35	23(33.33%)	10/13
PA(mg/L)			11.378	0.001
<170	31(44.93%)	16/15
Hb(g/L)			1.596	0.206
<120	41(59.42%)	27/14
ALC(×10^9/L)			3.555	0.059
<1	44(63.77%)	28/16
CD4(a/μL)			6.055	0.014
<200	43(62.32%)	26/17
LDH			0.776	0.378
Elevated	46(66.67)	31/15
Ann Arbor stage			2.817	0.093
III/IV	53(76.81%)	35/18
Pathological type			3.310	0.346
DLBCL	59(85.51%)	43/16
BL	6(8.70%)	4/2
PBL	1(1.45%)	1/0
Unclassified NHL	3(4.35%)	1/2
IPI(score)			24.291	0.000
Low-risk(0/1)	10(14.50%)	9/1
Moderate to low risk(2)	21(30.43%)	17/4
Moderate to high risk(3)	24(34.78%)	19/5
High risk(4/5)	14(20.29%)	4/10
Whether cART			1.299	0.254
No	36(52.17%)	23/13

Abbreviations: BMI, body mass index; ALB, albumin; PA, prealbumin; Hb, hemoglobin; ALC, absolute lymphocyte count; LDH, lactate dehydrogenase; DLBCL, diffuse large B-cell lymphoma; BL, Burkitt lymphoma; PBL, plasmablastic lymphoma; cART, highly active antiretroviral therapy.

Figure 1 The univariate survival function diagram of IPI, BMI, ALB, PA, and CD4 by the Kaplan–Meier method.

Table 3 Parameter Estimation and Test Results of the Cox Proportional Hazards Regression Model (χ²=38.107, P<0.001)

Factors	β	RR(95% CI)	P
Prealbumin	1.189	3.285(1.074–10.044)	0.037
IPI(Low-risk)		Indicator	-
IPI(Moderate to low risk)	0.513	1.670(0.165–16.897)	0.664
IPI(Moderate to high risk)	0.782	2.185(0.250–19.078)	0.479
IPI(High risk)	2.883	17.873(1.972–161.960)	0.010
BMI(normal)		Indicator	-
BMI(light)	0.935	2.546(0.704–9.214)	0.154
BMI(medium)	2.560	12.941(1.880–89.096)	0.009
BMI(heavy)	2.635	13.940(1.730–112.306)	0.013

Abbreviation: BMI, body mass index.

Figure 2 The multivariate survival function diagram of BMI, PA, and IPI score by the Cox risk regression analysis.

Table 4 The Area Under the Curve of the ROC of IPI, BMI, PA and the Composite Indicator (PA+IPI+BMI)

Factors	AUC(95% CI)	P
IPI	0.737(0.599–0.875)	0.002
BMI	0.708(0.569–0.847)	0.007
PA	0.790(0.675–0.905)	0.000
The composite indicator (PA+IPI+BMI)	0.874(0.786–0.962)	0.000

Abbreviations: BMI, body mass index; PA, prealbumin.

Figure 3 The ROC curve of IPI, BMI, PA, and the composite indicator (PA+IPI+BMI).